Oncode Scientific

The conviction that drives us

Empowering Clinicians

At Oncode, our core mission is to empower clinicians with clear and comprehensive genetic reports of the highest quality. Understanding and effectively using genetic information is essential for clinicians to make informed treatment decisions.

We develop genetic reports that are

User-friendly
with Colour-Guided

Comprehensive

Clear and Concise

We aim to enhance clinicians' ability to navigate and utilize the genetic insights in their clinical practice.

Product Features

Oncode has been a pillar of support for medical professionals and patients alike, delivering exceptional molecular diagnostic services that have proven indispensable in the field. With a well-established track record extending over nearly a decade, Oncode has consistently delivered top-tier services, making a significant contribution to the well-being of countless patients.

Professional Team
Report Visualization
Enhanced Flexibility
Patients' Monitoring
Precision & Accuracy
powerful Data Analysis

Professional Team

Oncode has a team of highly skilled professionals, who collectively offer a comprehensive range of services and unwavering support to physicians and patients. They include:

Enhanced Flexibility

Oncode offers highly customizable:

TESTING PANELS

MONITORING PANELS

These are tailored to meet the specific requirements of doctors and the unique conditions of patients, thereby providing precise and targeted guidance for effective treatment strategies.

At Oncode, we prioritize the incorporation of cutting-edge technologies and methodologies that emphasize both high sensitivity and extensive coverage in our testing procedures. This commitment allows us to minimize the occurrence of false negatives and false positives, ensuring that healthcare professionals receive the most reliable and informative results to make effective treatment decisions.

Precision & Accuracy

Oncode’s reports are designed with user-friendly feature :

intuitive charts

clear data presentation methods

This ensures and enables:

Report Visulisation

Patients’ Monitoring

At Oncode, our monitoring tests and data analysis system are designed for long-term continuity, enabling us to track patients’ conditions over extended periods. This approach allows us to:

Powerful Data Analysis

Oncode employs a series of robust quality checkpoints throughout the data analysis process and implements rigorous quality control procedures to guarantee the highest standards of accuracy and reliability in our test results. Our pursuit of paramount precision and dependability in our reports is underpinned by:

Star Products

SOLID TUMOURS
BLOOD CANCERS

LIQUID10

Liquid biopsy NGS panel targeting 10 actionable genes for mutations & fusions commonly mutated in cancer especially lung & colon cancer to provide treatment options & prognostic indications.

LIQUID100

Liquid biopsy NGS panel targeting >100 actionable genes in cancers for mutation, fusion and SNP to provide treatment options & prognostic indications.

HOMOLOGOUS
RECOMBINATION
DEFICIENCY
(HRD)

NGS panel to assess the status
of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability.

TISSUE
PREMIUM

NGS panel targeting mutation and fusion, MSI (PCR & Fragment analysis), PD-L1 (IHC) and blood germline NGS panel targeting genes associated with hereditary cancer predisposition, enabling the identification of somatic mutations as well as inherited cancer risks in individuals.

TISSUE10

FFPE NGS panel targeting 17 actionable genes for
mutations & fusions commonly mutated in cancers to provide treatment options & prognostic indications.

CANCER
HEREDITARY

Blood germline NGS panel targeting 31 genes
associated with hereditary cancer predisposition.

ONCODEcipher Lung Premium

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in lung cancer to provide treatment options & prognostic indications.

ONCODEcipher Breast & Ovarian Premium

FFPE DNA & blood  panel targeting relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

ONCODEcipher Breast & Ovarian Liquid Premium

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

ONCODEcipher Colon & Endometrial Premium

FFPE DNA & blood panel targeting 67 relevant genetic mutations in colon and endometrial  cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

ONCODEcipher Pancreatic & Prostate Premium

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in pancreatic and prostate cancer to provide treatment options & prognostic indications.

ONCODEcipher Tissue Premium

FFPE DNA & blood  panel targeting relevant and actionable genes commonly mutated in cancerous cell tissue  to provide treatment options & prognostic indications. 

ONCODEcipher Liquid Premium

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Learn More

ONCODEcipher Liquid Premium Plus

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients

For other products & info

How to order

CLINICIANS

step 1

Receive Specimen
Collection Kit from
Oncode

step 2

Fill up the Test
Requisition Form

step 3

Draw patient’s blood
into EDTA/ Streck
tubes AND/OR
prepare FFPE
slides/block

COURIER

step 4

Picks up kit and
delivers to Oncode
laboratory at room
temperature

ONCODE

step 5

Quantify and qualify
sample

step 6

Perform test
accordingly

step 7

Generate and send
reports to clinician
within stated
turnaround time

CLINICIANS

step 8

Interpret report to
patient

step 8

Proceed with
treatments and/or
subsequent test

CLINICIANS

step 1

Receive Specimen
Collection Kit from
Oncode

step 2

Fill up the Test
Requisition Form

step 3

Draw patient’s blood
into EDTA/ Streck
tubes AND/OR
prepare FFPE
slides/block

COURIER

step 4

Picks up kit and
delivers to Oncode
laboratory at room
temperature

ONCODE

step 5

Quantify and qualify
sample

step 6

Perform test
accordingly

step 7

Generate and send
reports to clinician
within stated
turnaround time

CLINICIANS

step 8

Interpret report to
patient

step 9

Proceed with
treatments and/or
subsequent test

For test ordering & additional info

Oncode Specimen Collection Kit containing :

Kindly fill up Test Requisition Form upon sample pick-up/ delivery. Patient’s pathology reports or clinical reports (if any) can be attached altogether.

FREQUENTLY ASKED QUESTIONS

  • Comprehensive panels with high sensitivity: Oncode provide clinicians with a comprehensive range of testing options, including both PCR and NGS tests. These testing options are designed to cater to the individual needs and circumstances, allowing for the selection of the most suitable test. With our rigorous validation and quality control processes, we achieve high sensitivity of up to  99.9% (LOD at 0.1%) and specificity of 100% in all of our NGS tests for every sample tested.
  • Exceptional Technical Support: Oncode offers unbeatable technical support throughout the testing process, from test selection to result interpretation. Our team of skilled scientists and physicians is readily available to provide support whenever needed. 
  • Color-Guided Proprietary Clinical Reports: Oncode’s clinical reports feature a unique color-guided format, providing concise interpretations and direct recommendations for the next steps. This is especially helpful in supporting busy clinicians with their patient treatment planning.
  • Thorough Validation and Quality Assurance: Oncode tests undergo comprehensive validation processes, consistently meeting external quality assurance (EAQ) standards such as CAP, EMQN, UKNEQAS, and RCPA through annual enrollments. Additionally, Oncode implements stringent quality controls, checkpoints, and continuous validations as standard practices to ensure the highest levels of accuracy and precision in the tests.
  • Outstanding Performance Indicators: Based on past years’ key performance indicators, Oncode achieves a fulfillment rate of 99.7% for all turnaround times, and 99.8% of customer satisfaction surveys rate Oncode as “good” and “excellent.” 
  • Reasonable Pricing: Oncode offers competitive and reasonable testing price, ensuring accessibility and affordability for customers.
  • Knowledge Sharing: Oncode is passionate about sharing knowledge and case studies obtained through our clinical practices. We actively publish these information on social media platforms, participate in exhibitions and conferences, and distribute medical bulletins to disseminate valuable insights and findings.
Both PCR and NGS are widely used to detect genetic alterations in cancers. The choice between a single PCR test and an NGS test depends on several factors:
  • Complexity and Coverage: PCR is simpler and easier to perform, but it has limited multiplex capability, meaning it can only analyze a few genes at a time. NGS, on the other hand, allows for simultaneous analysis of many genomic loci, providing a broader coverage of genetic alterations.
  • Sensitivity: NGS has a higher sensitivity, often reaching a limit of detection (LOD) as low as 0.1%, while PCR typically has a LOD of around 5%. This means that NGS is more likely to detect low-frequency mutations, while PCR’s lower sensitivity may result in the potential risk of missing well-known actionable mutations, leading to false negatives. 
  • Technical Demands and Cost: NGS is more technically demanding compared to PCR due to the need for specialized equipment, bioinformatics analysis, and skilled personnel. In terms of cost-effectiveness, NGS becomes more advantageous when analyzing multiple genes. This is because NGS enables the simultaneous analysis of multiple genes in a single test, reducing the overall cost per gene when compared to conducting individual PCR tests for each gene.
  • Time and Efficiency: NGS allows for simultaneous analysis of multiple genes, providing all the required data at once. This saves time compared to performing separate PCR tests for each gene of interest. Additionally, NGS avoids the need for multiple biopsies and repeated tests, saving specimen resources.
In summary, while PCR may be suitable for simpler analyses with a limited number of genes, NGS offers advantages in terms of coverage, sensitivity, and efficiency. It provides a comprehensive view of genetic alterations and allows for the analysis of multiple genes simultaneously. However, the decision should consider the specific requirements of your situation, including the genes of interest, sensitivity needs, available resources, and budget.
  • Liquid biopsy is a technique used to capture the circulating tumor DNA (ctDNA), which refers to small fragments of DNA released by cancerous cells and tumors into the bloodstream of cancer patients. The analysis of ctDNA has gained increasing importance in clinical practice for several reasons:
    • Non-invasive Detection: ctDNA analysis offers a non-invasive alternative to traditional tissue biopsies, providing a more accessible and less burdensome method for obtaining genetic information about tumors. Liquid biopsy is particularly useful in cases where tissue biopsy is not available (when tissue is inaccessible or limited). This has significant implications for early detection, monitoring treatment response, and assessing disease progression.
    • Tumor Heterogeneity: Tumors often consist of a heterogeneous population of cells with different genetic alterations. ctDNA provides a representative snapshot of the genetic diversity within a tumor, allowing for a more comprehensive understanding of tumor heterogeneity. This information is crucial for guiding personalized treatment strategies and monitoring the emergence of drug resistance mutations.
    • Disease & Treatment Monitoring: ctDNA analysis enables the monitoring of tumor dynamics. It can help track changes in tumor burden, detect minimal residual disease after surgery or treatment, identify disease recurrence earlier than traditional imaging methods, and assess treatment response and the emergence of resistance mutations. This allows for timely intervention and adjustment of treatment plans.
Our technical team is available to provide professional guidance and assist you in selecting the most suitable panel for your patients. They will consider factors such as type of cancer, test objectives, specific biomarkers of interest, and financial considerations to provide informed recommendations. Their expertise will help ensure that you make a well-informed decision regarding the most suitable panel for your patients’ needs. Please feel free to contact us if you require any assistance in selecting the most suitable panel.
Oncode offers a variety of test panels for different types of cancer. The complete list of genes included in each test panel can typically be found in the test form, product brochures, and sample reports specific to the test panel. For more detailed information about our tests, please feel free to contact us.
All the tests conducted in Oncode can be performed using either blood samples (for liquid biopsy panel or blood cancer panel) or formalin-fixed, paraffin-embedded (FFPE) tissues.
Oncode is dedicated to providing timely updates regarding the progress of the testing process. Upon receiving the test specimen, we perform an initial quality inspection and send an acknowledgement of receipt to the provided email address. This notification includes the status of the quality inspection, as well as details regarding the sample and test ordered, including the expected turnaround time (TAT) for the specific test. In the event that the test specimen does not pass the quality check, we will promptly notify you for further arrangements, such as providing a new FFPE tissue or coordinating the resampling of blood samples.
Genetic counseling is available if required to support patients throughout their genetic testing journey. Pre-test genetic counseling sessions aim to provide education about genetics, including an explanation of risk factors and the benefits of undergoing genetic testing. This session equips patients and their family members with the knowledge needed to make informed decisions regarding genetic testing.

Following the completion of genetic testing, post-testing genetic counseling sessions are conducted to help patients and their families understand the test results and their potential implications for future health. During these sessions, patients can explore strategies for managing their condition and discuss the risk of recurrence of the condition  in other family members.
The likelihood of a successful insurance claim depends on the specific policies of individual insurance companies. However, we have had positive experiences with major insurance companies, with success rates for claims exceeding 90%. Upon request, Oncode can assist by providing a Letter of Medical Necessity to support the insurance claim process.

It is important to note that insurance policies can vary between countries and different insurance companies. Therefore, we recommend contacting the local insurance company to ensure that patients are covered and to understand any potential differences in policy.

LIQUID 10

PRODUCT DESCRIPTION

Liquid biopsy NGS panel targeting 10 actionable genes for mutations and fusions commonly mutated in cancers to provide treatment options & prognostic indications.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements.

LIQUID 100

PRODUCT DESCRIPTION

Liquid biopsy NGS panel designed to target a comprehensive set of 100 over genes frequently found mutated in various cancers. This panel accurately identify genetic alterations and provide valuable insights into potential treatment options, prognostic indications, and implications for chemotherapy recommendations.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, ERBB2, BRCA1, BRCA2, NTRK1-3, DPYD, CYP2D6, UGT1A1, etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements, CNVs, SNPs.

Homologous
Recombination
Deficiency (HRD)

PRODUCT DESCRIPTION

NGS panel to assess the status of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability. HRD status has prognostic and therapeutic implications that are important to identify the magnitude of benefit of PARP inhibitors during treatment planning.

HIGHLIGHTED GENES

BRCA1, BRCA2, and genomic instability (LOH: Loss of heterozygosity, LST: Large-scale state transitions, and TAI: Telomeric-allelic imbalance markers).

NCCN RECOMMENDS HRD TESTING FOR

Ovarian, fallopian tube and primary peritoneal cancers.

TISSUE PREMIUM

PRODUCT DESCRIPTION

This test comprises of two assays: 1) NGS panel that focuses on detecting mutations, fusions, MSI (PCR and fragment analysis techniques) and PD-L1 (IHC). 2) Germline NGS panel, which specifically targets 31 genes known to be associated with hereditary cancer predisposition. This panel offers a thorough assessment of genetic alterations, enabling the identification of somatic mutations as well as inherited cancer risks in individuals.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, BRAF, ESR1, PIK3CA, TP53, NTRK1-3, MLH1, MSH2, MSH6, MSI, PD-L1 and etc.

ALTERATIONS DETECTED

SNVs, InDels, MSI, Large Genomic Rearrangements, Large Deletion/Duplications, CNVs and PD-L1.

TISSUE 10

PRODUCT DESCRIPTION

FFPE NGS panel targeting 17 actionable genes commonly mutated in cancers to provide treatment options & prognostic indications.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, NTRK1-3, STK11, KEAP1 etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements.

CANCER HEREDITARY

PRODUCT DESCRIPTION

NGS panel specifically designed to target 31 germline genes known to be associated with hereditary cancer predisposition. This panel detects genetic variations in these genes, enabling the identification and assessment of potential inherited cancer risks in individuals.

HIGHLIGHTED GENES

Germline BRCA1&2, BARD1, PALB2, CHEK2, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM, etc.

ALTERATIONS DETECTED

SNVs, InDels, Large Genomic Rearrangements, Large Deletion/ Duplications and CNVs

ONCODEcipher Lung Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in lung cancer to provide treatment options & prognostic indications.

Highlighted Genes -- EGFR, ALK, ROS1, RET, BRAF, MET, PDL1 etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 15ml Blood in cfDNA tubes
  • FFPE Block or 15 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Breast & Ovarian Premium NGS panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Somatic BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27 (immunotherapy), MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in EDTA tubes
  • FFPE Block or 10 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Breast & Ovarian Liquid Premium NGS panel

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 15ml Blood in cfDNA tubes (2 tubes)

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Colon & Endometrial Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting 67 relevant genetic mutations in colon and endometrial cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

Highlighted Genes -- Mutations of RAS/ RAF/ MEK/ MAP kinase signaling pathway, NR-21, NR-24, BAT-25, BAT-26, MONO-27 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 10-15 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Pancreatic & Prostate Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in pancreatic and prostate cancer to provide treatment options & prognostic indications.

Highlighted Genes -- KRAS, TP53, CDKN2A, SMAD4, NTRK1,2,3, NR-21, NR-24, BAT-25, BAT-26, MONO-27, Germline BRCA1,2, MLH1, MSH2, EPCAM and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 25 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Tissue Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in cancerous cell tissue to provide treatment options & prognostic indications.

Highlighted Genes --NTRK1,2,3,PDL-1, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 30 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid Premium NGS Panel

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 30ml Blood in cfDNA tubes (4 tubes)

TAT

Turn Around Time:

15 Working Days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

ONCODEcipher Liquid Premium Plus NGS Panel

Technique:

Next Generation Sequencing (NGS)

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 30ml Blood in cfDNA tubes (4 tubes)

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

EOSINOPHILIA FUSION NGS Panel

PRODUCT DESCRIPTION

NGS panel to detect all fusions/rearrangements in PDGFRA, PDGFRB, FGFR1, BCR, ABL1, FLT3, ETV6 and JAK2 & mutation in KIT which is useful in the assessment of Eosinophilia and Mastocytosis.

HIGHLIGHTED GENES

PDGFRA (including FIP1L1::PDGFRA), PDGFRB, FGFR1, BCR, ABL1, FLT3, ETV6 and JAK2 (including PCM1::JAK2) & mutation in KIT.

MUTATION 37-GENE NGS Panel

 

PRODUCT DESCRIPTION

NGS panel to detect 37 gene mutations which allows a broader exploration on the genes implicated in MPN & AML/MDS.

HIGHLIGHTED GENES

ABL1, ASXL1, CALR, CSF3R, DNMT3A, EZH2, JAK2, KIT, MPL, NPM1, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, ZRSR2 etc.

FUSION 87-GENE NGS Panel

PRODUCT DESCRIPTION

NGS Panel detecting 87 gene fusions implicated in ALL including fusions identifying Ph-like BCR-ABL1 negative B-ALL.

HIGHLIGHTED GENES

ABL1, ABL2, CRLF2, CSF1R, EPOR, ETV6, JAK2, KMT2A, P2RY8, PAX5, PDGFRA, PDGFRB, PTK2B, RUNX1, TCF3, TYK2 etc.

AML COMBO PLUS (Mutation & Fusion) NGS Panel

PRODUCT DESCRIPTION

Comprehensive NGS panel for AML detecting mutation (23 genes) and rearrangement/ fusion (11 genes) commonly implicated in AML to provide possible prognostic, therapeutic and diagnostic options.

HIGHLIGHTED GENES

FLT3-ITD & TKD, NPM1, CEBPA, IDH1/2, RUNX1, CBFB, MLL/KMT2A etc.

ABL1 Kinase Domain Mutation NGS Panel

PRODUCT DESCRIPTION

NGS Panel to detect Tyrosine Kinase Inhibitors (TKIs) resistance mutations in ABL1 kinase domain and all possible BCR::ABL1 fusions.

HIGHLIGHTED GENES

BCR::ABL1 fusion, mutation in ABL1 kinase domain (amino acid positions 244-396)

MPN PCR PANEL

PRODUCT DESCRIPTION

PCR-based test for the detection of mutations in JAK2, CALR & MPL

HIGHLIGHTED GENES

JAK2 V617F & exon 12, CALR, MPL W515K/L/A & S505N

BRAF V600E QUALITATIVE PCR Panel

PRODUCT DESCRIPTION

Qualitative PCR assay to detect the presence of BRAF V600E variant which is useful in the assessment of Hairy Cell Leukemia

HIGHLIGHTED GENES

BRAF V600E

MYD88 L265P QUALITATIVE PCR Panel

PRODUCT DESCRIPTION

Qualitative PCR assay to detect the presence of MYD88 L265P somatic variants which is useful for diagnostic of CD5 negative B-NHL and DLBCL.

HIGHLIGHTED GENES

MYD88 L265P